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Abstract
Background Atrial high rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs) are associated 
with an increased risk of stroke. However, the impact of AHRE on improving stroke risk stratification scheme remains 
uncertain.
Objective The purpose of this study was to assess the impact of AHRE on prognosis in relation with cardiovascular events 
and risk stratification.
Methods A total of 856 consecutive patients who had dual-chamber CIEDs implanted were retrospectively analyzed. To 
detect AHREs, they were monitored for 6 months after CIEDs’ implantation and were followed for a mean of 4.0 years for 
clinical outcomes such as thromboembolism or death.
Results Overall, 125 (14.6%) of patients developed AHREs within the first 6 months (median age 72.0 years, 39.3% female). 
Patients with AHREs had a high rate of thromboembolism (2.6%/year) and mortality (3.0%/year). On multivariate analy-
sis, AHRE was significantly associated with increased risk of thromboembolism [hazard ratio (HR) 3.40; 95% confidence 
interval (CI) 1.38–8.37, P = 0.01] and death (HR 3.47; 95% CI 1.51–7.95; P < 0.01). The predictive abilities of the  CHADS2 
and  CHA2DS2-VASc scores were modest, with no significant improvements by adding AHRE to those scores. However, 
the integrated discrimination improvement and net reclassification improvement showed that the addition of AHRE to the 
 CHADS2 and  CHA2DS2-VASc scores statistically improved their predictive ability for the composite outcome.
Conclusions AHRE was an independent factor associated with increased risk of clinical outcomes. The addition of AHRE 
to the clinical risk scores significantly improved discrimination for thromboembolism or death.
Keywords Atrial fibrillation · Atrial high rate episode · Cardiac implanted electronic device · Risk stratification scheme
Introduction
Atrial fibrillation (AF) is the most common sustained 
arrhythmia, and is associated with increased risks of mor-
bidity and mortality [1]. Integrated management including 
anticoagulation therapy in patients with AF is increasingly 
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recognized [2, 3], but there are still a substantial number of 
AF patients admitted with stroke, heart failure, and other 
complications [4, 5]. This can be to some extent due to 
asymptomatic nature of AF as approximately one-third of 
patients did not report any symptoms commonly attribut-
able to AF (e.g., palpitations, shortness of breath, or chest 
pain) [6], leading to a prolonged delay in AF diagnosis and 
timely initiation of anticoagulation therapy. In many cases, 
asymptomatic AF is diagnosed only after the onset of com-
plications such as ischemic stroke or congestive heart failure 
has occurred [7].
Subclinical and asymptomatic atrial tachyarrhythmias 
often precede the development of clinical AF, and can be 
detected by continuous cardiac monitoring technology 
including cardiac implantable electronic devices (CIEDs, 
e.g., permanent pacemakers, implantable cardioverter defi-
brillators [ICD], and cardiac resynchronization therapy 
[CRT] devices) [8]. Previous studies demonstrated that 
atrial high rate episodes (AHREs) detected by CIEDs have a 
high correlation with clinically documented AF [9], and are 
independently associated with an increased risk of ischemic 
stroke and systemic embolism [10–12].
Various efforts have been made to identify the risk factors 
for the development of AHRE and to assess the relation-
ship between AHREs and clinical outcomes in patients with 
CIEDs. Although recent studies have investigated the impact 
of AHRE on the management of patient with AHREs, the 
optimal management of such patients remains uncertain in 
the current clinical guidelines, especially anticoagulation 
therapy in patients with AHREs [13].
In this study, we aimed to investigate the clinical charac-
teristics of AHRE in a ‘real-world’ cohort of patients with 
CIEDs, and assessed the impact of AHRE on prognosis in 




The consecutive patients receiving pacemaker, ICD, and 
CRT devices, who attended the cardiology department 
of Sandwell and West Birmingham Hospitals NHS Trust 
(Sandwell General Hospital and City Hospital) in Birming-
ham, United Kingdom were retrospectively enrolled. In the 
present study, patients with single-chamber CIEDs (i.e., VVI 
and AAI devices) and patients with < 6 months of follow-up 
were excluded.
We retrospectively reviewed the patients’ medical 
records, and collected clinical information on demographics, 
co-morbidities, and concomitant medications. Prior history 
of AF was defined as a documented AF on 12-lead ECG or 
Holter ECG monitoring.
Atrial high rate episode and clinical outcomes
The device diagnostic information was interrogated to assess 
whether patients had developed AHREs or not within the 
first 6 months since the time of CIEDs’ implantation. All 
CIEDs were programmed to the nominal setting, which 
detected any episodes of arrhythmia. We defined the AHRE 
as an episode lasting at least 5 min with atrial rate ≥ 175 
beats per minute, given that previously published stud-
ies suggested that the 5 min cut-off value excluded most 
episodes of over-sensing due to mechanical problems and 
appropriately detected clinical AF [9]. Device diagnostic 
information on AHREs was reviewed by at least 1 expe-
rienced electrophysiologist, blinded to clinical outcomes.
The endpoint for the present study was the occurrence 
of thromboembolism (ischemic stroke, transient ischemic 
attack [TIA], or systemic embolism) or all-cause death 6 
months after CIEDs’ implantation. Baseline characteris-
tics of patients with and without AHREs were compared, 
and the predictive ability of  CHADS2 and  CHA2DS2-VASc 
scores for clinical outcomes was assessed. This study was 
conducted in accordance with the EU Guidance on Good 
Clinical Practice CPMP/ ECH/135/95. The present study 
was approved by the local research ethics committee and 
complied with the Declaration of Helsinki. All patients 
included in the study had there data anonymised.
Statistical analysis
Continuous variables were presented as means and standard 
deviations (SD), unless not normally distributed, in which 
case medians and interquartile ranges (IQR) were used. Cat-
egorical variables were presented as frequencies and per-
centages. Censoring was done for the first event recorded. 
We compared categorical variables using Chi-square test and 
continuous variables using independent samples t test for 
normally distributed data or Mann–Whitney U test for non-
normal distribution. Baseline characteristics, stroke risk pro-
files, and medications were tabulated between patients with 
and without AHREs. Annual incidence rates for the compos-
ite and individual endpoints were recorded in patients with 
and without AHREs. Kaplan–Meier survival curves were 
depicted, and differences were assessed by log-rank test. 
The independent effects of AHRE on the clinical outcomes 
were assessed using a Cox proportional hazards regression 
model including components of the  CHA2DS2-VASc score 
(age assessed as a continuous variable), prior history of AF, 
and oral anticoagulant (OAC) use as co-varieties.
Receiver-operating characteristic (ROC) curve analysis 
was performed to test the predictive discrimination of the 
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risk scores for clinical outcomes based on an area under 
the ROC curve (AUC). To compare the predictive ability of 
the predictive models, we calculated the statistical differ-
ence between the AUCs with the method of DeLong et al. 
[14] Furthermore, improvements in the predictive accuracy 
of the models were evaluated by calculating the integrated 
discrimination improvement (IDI) and the net reclassifica-
tion improvement (NRI), as described by Pencina et al. [15].
We also assessed the clinical usefulness and net benefit of 
the predictive models using decision curve analysis (DCA), 
as described by Vickers et al. [16]. This analysis identifies 
patients who will have any of the adverse events evaluated, 
based on the predictions of the modified risk score in com-
parison with the original. The clinical net benefit is calcu-
lated by summing the benefits (true positive) and subtracting 
the harms (false positive). The result of this analysis is pre-
sented with the selected probability threshold plotted on the 
x-axis and the benefit of the evaluated model on the y-axis.
All statistical analyses were performed using IBM SPSS 
Statistics version 24.0 software (IBM Corp) and R soft-
ware packages version 3.5.1 (R Development Core Team). 




Baseline characteristics of patients with and without AHREs 
are shown in Table 1. Median age of the patients was 72.0 
(IQR: 62.0–80.0) years, and 336 (39.3%) were female. Of 
856 patients with CIEDs, 74.6% had pacemaker, 15.0% ICD, 
and 10.4% CRT. During a mean follow-up of 48.2 ± 32.3 
months, 125 (14.6%) of patients developed AHREs in the 
first 6 months. Patients with AHREs were older, with a 
higher prevalence of prior AF (and accordingly higher use of 
oral anticoagulants and digoxin, lower use of antiplatelets), 
compared to those without AHREs. No significant differ-
ences in mean  CHADS2 and  CHA2DS2-VASc scores were 
found between two groups.
Table 1  Baseline characteristics 
of patients with and without 
AHRE
ACE-I angiotensin-converting enzyme inhibitor, AF atrial fibrillation, AHRE atrial high rate episode, ARB 
angiotensin II receptor blocker, BMI body mass index, IQR interquartile range, OAC oral anticoagulant, 
TIA transient ischemic attack
Overall (n = 856) AHRE (n = 125) No AHRE (n = 731) P value
Demographics
 Age, median (IQR) 72.0 (62.0–80.0) 74 (63.0–81.0) 71.0 (62.0–79.0) 0.03
 Age 65–74 y 232 (27.1) 29 (23.2) 203 (27.8) 0.29
 Age > 75 y 383 (44.7) 66 (52.8) 317 (43.4) 0.05
 Female gender [no., (%)] 336 (39.3) 342 (33.6) 294 (40.2) 0.16
 BMI, median (IQR) 27.9 (24.6–31.7) 27.4 (23.5–31.8) 28.0 (24.6–31.5) 0.41
Medical history [no., (%)]
 Hypertension 603 (70.4) 91 (72.8) 512 (70.0) 0.53
 Diabetes mellitus 241 (28.2) 36 (28.8) 205 (28.0) 0.86
 Dyslipidemia 554 (68.6) 81 (68.6) 473 (68.7) 1.00
 Heart failure 214 (25.0) 39 (31.2) 175 (23.9) 0.08
 Prior stroke/TIA 92 (10.7) 15 (12.0) 77 (10.5) 0.63
 Vascular disease 317 (37.0) 48 (38.4) 269 (36.8) 0.73
 Prior history of AF 212 (24.8) 75 (60.0) 137 (18.7) < 0.001
Thromboembolic risk, mean ± SD
 CHADS2 score 1.9 ± 1.2 2.0 ± 1.3 1.9 ± 1.2 0.07
 CHA2DS2-VASc score 3.4 ± 1.6 3.5 ± 1.7 3.3 ± 1.6 0.22
Medications [no., (%)]
 Beta-blocker 270 (35.5) 47 (40.9) 223 (34.5) 0.19
 ACE-I/ARB 436 (56.7) 66 (57.4) 370 (56.6) 0.87
 Diuretics 276 (35.8) 42 (36.5) 234 (35.7) 0.87
 Statin 509 (66.0) 74 (64.3) 435 (66.3) 0.68
 OAC 151 (19.7) 54 (47.0) 97 (14.9) < 0.001
 Antiplatelet 396 (51.4) 49 (42.2) 347 (53.0) 0.03
 Digoxin 38 (4.9) 12 (10.4) 26 (4.0) 0.003
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Clinical outcomes and atrial high rate episode
During the follow-up, the observed rates of thromboem-
bolism, all-cause death and composite outcome were 4.2% 
(n = 36), 5.4% (n = 46) and 9.3% (n = 80), respectively 
(Table 2). Patients with AHREs had a higher risk of throm-
boembolism (incidence 2.6%/year) compared with those 
without AHREs (incidence 0.9%/year) [hazard ratio (HR) 
2.703, 95% confidence interval (CI) 1.52–4.81, P < 0.001]. 
Similarly, patients with AHREs had higher risk of all-cause 
death and composite outcome (thromboembolism or all-
cause death) than those without AHREs (3.0%/year vs. 1.1%/
year, HR 3.85, 95% CI 1.90–7.80, P < 0.001 for all-cause 
death; 5.4%/year vs. 2.0%/year, HR 3.32, 95% CI 1.95–5.65, 
P < 0.001 for the composite outcome). In a subgroup analy-
sis of patients who had no prior history of AF, patients with 
AHREs tended to have a higher risk of thromboembolism 
compared with those without AHREs, but not statistically 
significant. On the other hand, patients with AHREs had a 
significantly higher risk of all-cause death compared with 
those without AHREs (Supplementary Table 1).
Kaplan–Meier curve analysis shows that crude event-free 
survival for thromboembolism, all-cause death and compos-
ite outcome appeared to be lower in patients with AHREs 
than those without AHREs (P = 0.006, P < 0.001, P < 0.001, 
respectively) (Fig. 1). On multivariate Cox proportional 
hazards regression analysis (Table 3), age was significantly 
associated with increased risk of all-cause death and the 
composite outcome (HR 1.13, 95% CI 1.08–1.18, P < 0.001, 
HR 1.06, 95% CI 1.03–1.09, P < 0.001, respectively); heart 
failure with all-cause death (HR 2.21, 95% CI 1.03–4.74, 
P = 0.04); prior stroke or TIA with thromboembolism and 
composite outcome (HR 2.64, 95% CI 1.16–5.99, P = 0.02, 
HR 2.23, 95% CI 1.25–3.96, P = 0.006, respectively). Prior 
history of AF was not an independent factor associated with 
any outcomes (all P > 0.05). Similarly, the use of OAC was 
not significantly associated with any outcomes (all P > 0.05), 
although the association trended towards being protective.
On multivariate adjustment, AHRE was significantly 
associated with increased risk of all outcomes (HR 3.40, 
95% CI 1.38–8.37, P = 0.008 for thromboembolism, HR 
3.47, 95% CI 1.51–7.95, P = 0.003 for all-cause death, and 
HR 3.52, 95% CI 1.89–6.55, P < 0.001 for the composite 
outcome).
When we performed a subgroup analysis of patients 
without prior history of AF (n = 644) and those with prior 
history of AF (n = 212), multivariate Cox regression analy-
sis showed that the impact of AHRE slightly weakened 
rather than entire population, but still significant on the 
clinical outcomes, especially all-cause death and the com-
posite outcome (Supplementary Tables 2 and 3).
Adding AHRE to the  CHADS2 and  CHA2DS2‑VASc 
scores for predicting clinical outcomes
ROC curve analysis showed that the predictive abilities 
of the  CHADS2 and  CHA2DS2-VASc scores were mod-
est and there were no significant improvements after add-
ing AHRE to the  CHADS2 and  CHA2DS2-VASc scores 
 (CHADS2: AUCs 0.60 to 0.61, P = 0.29 for thromboembo-
lism; AUCs 0.65 to 0.65, P = 0.73 for all-cause death; and 
AUCs 0.63 to 0.64, P = 0.32 for the composite outcome, 
 CHA2DS2-VASc: AUCs 0.60 to 0.61, P = 0.35 for throm-
boembolism; AUCs 0.68 to 0.68, P = 0.68 for all-cause 
death; and AUCs 0.65 to 0.65, P = 0.33 for the composite 
outcome) (Table 4).
Based on the IDI and the NRI, the addition of AHRE 
to the  CHADS2 and  CHA2DS2-VASc scores statisti-
cally improved discriminative value for composite out-
come  (CHADS2: IDI 0.01, P = 0.03; NRI 0.20, P = 0.04, 
 CHA2DS2-VASc: IDI 0.01, P = 0.02; NRI 0.20, P = 0.04), 
but not for thromboembolism and all-cause death 
 (CHADS2: IDI 0.002, P = 0.09; NRI 0.23, P = 0.12, 
for thromboembolism, IDI 0.004, P = 0.10; NRI 0.20, 
P = 0.13, for all-cause death,  CHA2DS2-VASc: IDI 0.002, 
P = 0.08; NRI 0.22, P = 0.18, for thromboembolism; IDI 
0.004, P = 0.11; NRI 0.20, P = 0.13, for all-cause mortal-
ity) (Table 4).
DCA graphically demonstrated that there were minimal 
net benefits of the addition of AHRE to the  CHADS2 and 
 CHA2DS2-VASc scores for predicting thromboembolism 
(Fig. 2a), all-cause death (Fig. 2b), and composite out-
come (Fig. 2c).
Table 2  Clinical outcomes after first 6 months in patients with and without AHRE
AHRE atrial high rate episode, CI confidence intervals, HR hazard ratio
Clinical outcomes Overall (n = 856) 
[no. (%)]
Patients with AHRE 
(n = 125)
Patients without AHRE 
(n = 7310
Unadjusted HR (95% CI) P value
No. of events %/year No. of events %/year
Thromboembolism 36 (4.2) 9 2.6 27 0.9 2.703 (1.52–4.81) < 0.001
All-cause death 46 (5.4) 11 3.0 35 1.1 3.845 (1.90–7.80) < 0.001
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Discussion
The main finding of the present study is that AHRE 
detected by CIEDs was an independent factor associated 
with significantly increased risks of thromboembolism and 
all-cause death, regardless of the presence or absence of 
prior history of AF. Second, the addition of AHREs to the 
 CHA2DS2-VASc score statistically improved its discrimi-
nation ability for the composite outcome of thromboembo-
lism or all-cause death. This is a contemporary ‘real-world’ 
cohort of patients with CIEDs, in relation with AHRE. To 
the best of our knowledge, no previous study has investi-
gated the clinical impact of AHRE on risk stratification for 
thromboembolism and all-cause death.
The widespread use of the CIED technology in the man-
agement of a broad spectrum of cardiac diseases (i.e., brady-
cardia, life-threatening tachycardia, and heart failure) offers 
the long-term continuous ECG monitoring, which allows 
an early detection of atrial tachyarrhytmias including AF 
before they become clinically evident [17]. However, most 
of AHREs are asymptomatic, short-lasting, and hard to be 
detected by the conventional methods such as 12-lead ECG 
or ambulatory Holter ECG monitoring. The reported inci-
dence of AHRE in patients with CIEDs is relatively vari-
able across studies, ranging from 30 to 70% [18]. Although 
the incidence may strongly depend on the clinical profile 
of study population, the previous studies have consistently 
reported that AHRE is associated with a substantial risk of 
subsequent development of clinically diagnosed AF, and is 
also associated with an increased risk of ischemic stroke 
and death [10–12]. However, the absolute risk of stroke in 
patients with AHREs may be lower than in those with clini-
cal AF.
In general, AF is known to be associated with fivefold 
risk of stroke compared to normal sinus rhythm, while 
recent meta-analysis showed that the annual rate of stroke 
in patients with AHREs was 1.89/100 person-year with 
2.4-fold increased risk of stroke compared to those without 
AHREs [19]. In the present study, AHRE was significantly 
associated with a threefold greater risk of thromboembo-
lism and of all-cause death. Our findings reinforce the evi-
dence that AHRE may not hold the same adverse prognosis 
as clinical AF, but may be considered as an early stage of 
clinical AF carrying an intermediate risk of stroke. On the 
other hand, the incidences of clinical outcomes in the pre-
sent study were relatively higher than the previous studies 
including general AF population. This may be due to the 
differences in baseline medical history, as in our study, half 
of patients were elderly (i.e., > 75 years) with a high propor-
tion of hypertension, dyslipidemia, and vascular disease. The 
Fig. 1  Kaplan–Meier curve analysis for thromboembolism (a), all-
cause death (b), and composite outcome (c)
▸
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present study included patients with not only pacemaker, 
but also those with ICD and CRT, who frequently have left 
ventricular dysfunction and/or ischemic heart disease and 
are at risk of sudden cardiac death.
Interestingly, we found that prior history of clinical AF 
was more frequently observed in patients with AHREs, but 
this was not independent factor associated with any out-
comes in Cox proportional hazards regression models. This 
can be explained by the fact that CIEDs’ implantation itself 
could suppress new AF development. Previous studies have 
demonstrated that dual-chamber pacing modes reduce the 
incidence of AF in patients with sick sinus syndrome [20, 
21]. In patients with CRT, hemodynamic improvement due 
to synchronized bi-ventricular pacing is reported to decrease 
the incidence of AF [22]. Furthermore, in a previous study 
of a heart failure cohort, there was no significant difference 
in the cumulative probability of developing thromboembolic 
events between AHRE patients with and without history of 
AF [23]. Of note, the subgroup analysis of patients without 
prior history of AF demonstrated that we found a significant 
association between AHRE and clinical outcomes, although 
there were a relatively small number of patients and clinical 
Table 3  Multivariable Cox regression analysis for clinical outcomes
Adjusted covariates including components of the  CHA2DS2-VASc score (age assessed as a continuous variable), prior AF documentation, OAC 
use, and AHRE lasting at least 5 min
AF atrial fibrillation, AHRE atrial high rate episode, CI confidence intervals, HR hazard ratio, OAC oral anticoagulant, TIA transient ischemic 
attack
Outcomes and variables Thromboembolism All-cause death Composite outcome
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age 1.01 (0.98–1.04) 0.54 1.13 (1.08–1.18) < 0.001 1.06 (1.03–1.09) < 0.001
Female gender 1.01 (0.48–2.13) 0.97 1.16 (0.60–2.25) 0.65 1.17 (0.71–1.93) 0.54
Hypertension 1.28 (0.50–3.26) 0.61 0.80 (0.36–1.79) 0.59 0.97 (0.53–1.77) 0.91
Diabetes mellitus 1.50 (0.73–3.08) 0.27 1.68 (0.86–3.28) 0.13 1.56 (0.96–2.54) 0.07
Heart failure 0.60 (0.24–1.53) 0.29 2.20 (1.03–4.74) 0.04 1.31 (0.73–2.35) 0.37
Prior stroke/TIA 2.64 (1.16–5.99) 0.02 2.17 (0.99–4.73) 0.05 2.23 (1.25–3.96) 0.01
Vascular disease 1.64 (0.78–3.42) 0.19 1.03 (0.50–2.10) 0.94 1.28 (0.77–2.14) 0.34
Prior history of AF 1.08 (0.43–2.71) 0.88 0.95 (0.42–2.18) 0.91 0.97 (0.52–1.80) 0.92
OAC use 0.66 (0.24–1.81) 0.42 0.50 (0.19–1.32) 0.16 0.51 (0.25–1.03) 0.06
AHRE 3.40 (1.38–8.37) 0.01 3.47 (1.51–7.95) 0.003 3.52 (1.89–6.55) < 0.001
Table 4  Comparison of the 
ROC curve, IDI and NRI of the 
 CHADS2 vs.  CHADS2 + AHRE 
and  CHA2DS2-VASc vs. 
 CHA2DS2-VASc + AHRE in 
predicting outcomes
AHRE atrial high rate episode, CI confidence interval, IDI integrated discriminatory improvement, NRI net 
reclassification improvement, ROC receiver-operating characteristic
*For C-statistic comparison
Clinical outcomes and risk scores C-statistic 95% CI P value* IDI P value NRI P value
Thromboembolism
 CHADS2 0.56 0.50–0.69 0.29 0.002 0.09 0.23 0.12
 CHADS2 + AHRE 0.61 0.52–0.70
 CHA2DS2-VASc 0.60 0.52–0.68 0.35 0.002 0.08 0.22 0.18
 CHA2DS2-VASc + AHRE 0.61 0.53–0.69
All-cause death
 CHADS2 0.65 0.58–0.72 0.73 0.004 0.100 0.20 0.13
 CHADS2 + AHRE 0.65 0.58–0.72
 CHA2DS2-VASc 0.68 0.60–0.75 0.68 0.004 0.11 0.20 0.13
 CHA2DS2-VASc + AHRE 0.68 0.61–0.75
Composite outcome
 CHADS2 0.63 0.57–0.69 0.32 0.01 0.03 0.20 0.04
 CHADS2 + AHRE 0.64 0.58–0.70
 CHA2DS2-VASc 0.65 0.59–0.70 0.33 0.01 0.02 0.20 0.04
 CHA2DS2-VASc + AHRE 0.65 0.60–0.71
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events. Thus, current actual AF burden (i.e., AHRE) has a 
more significant impact on clinical outcomes rather than a 
previously documented history of AF.
In the present study, we showed the modest predictive 
abilities of the  CHADS2 and the  CHA2D2-VASc scores for 
risk of clinical outcomes, even in the subgroup of patients 
with and without prior history of AF. Possible explanations 
for the modest predictive performance in the CIED popu-
lation include the differences in baseline medical history 
between the general AF population and CIEDs’ popula-
tion, and the suppression of new AF episodes after CIEDs’ 
implantation, which may affect the predictive ability of 
clinical risk scores in this patient population. However, 
AHRE has previously been reported to help to refine event-
risk stratification in such patients. Botto et al. demonstrated 
that combination of the data on AHRE with the  CHADS2 
score divided patients with CIEDs into two subpopulations 
with significantly different risks of thromboembolic events 
[24]. Furthermore, Boriani et al. reported that the addition 
of AHRE burden to the  CHADS2 and  CHA2DS2-VASc 
scores significantly improved their C-statistics [25]. In the 
present study, ROC curve analysis indicated no significant 
improvements of C-statistics by adding the data on AHREs 
to the clinical risk scores, but we showed a statistically sig-
nificant improvement of its discriminatory value and a net 
clinical benefit using the IDI, NRI and (minimally) DCA. 
The present study can provide novel insights into the cur-
rent management in this field, among ‘real-world’ patients 
with CIEDs.
Current guidelines do not address in detail the manage-
ment of patients with AHREs. Therefore, further stud-
ies are needed to explore the role of AHRE for event-risk 
stratification and decision-making for thromboprophylaxis 
in AHRE. Some prospective clinical trials are ongoing, 
which are investigating the benefit of OACs in patients with 
CIEDs, and will provide useful information on management 
of patients with AHREs [26, 27].
Limitations
There are several limitations in the present study. First, this 
is a single-center, retrospective, and observational study in a 
hospital-based setting. A relatively small number of patients 
were included in the present study, which may have reduced 
the detection power and possibly influenced the validity of 
some interactions. Second, we collected the clinical data at 
the time of CIEDs’ implantation, while the data at follow-up 
were not taken into account. As expected, initiation and dis-
continuation of OAC during follow-up would affect clinical 
outcomes, and we had limited information on this. Finally, 
data on quality of anticoagulation such as international nor-
malized ratio or time in therapeutic range were not available 
in the present study. Notwithstanding the relatively modest 
size and residual confounding, we found no significant rela-
tionship between OAC use and thromboembolism in multi-
variate Cox regression analysis.
Conclusion
In conclusion, AHRE was an independent factor associated 
with increased risk of clinical outcomes. The addition of 
AHRE to the  CHADS2 and  CHA2DS2-VASc scores signifi-
cantly improved discrimination for thromboembolism or 
death.
Fig. 2  Decision curve analysis for predicting cardiovascular events (a 
thromboembolism, b all-cause death, and c composite outcome)
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